SCHEMBL1574080

SCHEMBL1574080

CCOC(=O)c1cccc(N(C=O)CC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
KDM4E B2RXH2 1/20 0.51
TP53 P04637 1/20 0.49
POLB P06746 1/20 0.49
HPGD P15428 1/20 0.49
CYP4F2 P78329 1/20 0.49
CYP4A11 Q02928 1/20 0.49
LMNA P02545 3/20 0.48
MAPT P10636 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
ALDH1A1 P00352 4/20 0.48
MAPK1 P28482 1/20 0.48
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26144269 0.87 LOXL2 (0.49) SMN1; SMN2NPC1RAB9AKDM4ETP53
SCHEMBL1574716 0.83 CYP4F2 (0.52) SMN1; SMN2NPC1RAB9AKDM4ECYP4F2
SCHEMBL15014144 0.82 LMNA (0.53) SMN1; SMN2NPC1RAB9AKDM4ECYP4F2
SCHEMBL3236449 0.81 MAPT (0.65) SMN1; SMN2NPC1RAB9AKDM4EPOLB
SCHEMBL32685467 0.81 MAPT (0.65) SMN1; SMN2NPC1RAB9AKDM4EPOLB
SCHEMBL4926537 0.80 CYP4F2 (0.52) SMN1; SMN2NPC1RAB9APOLBCYP4F2
SCHEMBL10106391 0.79 CYP4F2 (0.49) SMN1; SMN2NPC1RAB9AKDM4ECYP4F2
SCHEMBL6445553 0.79 MAPT (0.53) SMN1; SMN2NPC1RAB9APOLBCYP4F2
SCHEMBL110276 0.79 CYP4F2 (0.65) SMN1; SMN2NPC1RAB9AKDM4ECYP4F2
SCHEMBL13153194 0.78 CYP4F2 (0.48) SMN1; SMN2NPC1RAB9AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1342719-B1 Benzodiazepine derivatives useful as CCK-Receptor Antagonists FERRING BV (NL) 2011-04-13 EP disclosed
EP-1342719-A1 Benzodiazepine derivatives useful as CCK-Receptor Antagonists YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-09-10 EP disclosed
US-5962451-A GASTROINTESTINAL DISORDERS; ANTIULCER AGENT; ANTICANCER AGENTS; SIDE-EFFECT REDUCTION FERRING BV (NL) 1999-10-05 US disclosed
US-5688943-A CHOLECYSTOKININ ANTAGONIST; ANTIULCER AGENTS; PSYCHOLOGICAL DRUGS; ANXIOLYTIC AGENTS; CONTROLLING APPETITE YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1997-11-18 US disclosed
EP-0628033-A1 BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1994-12-14 EP disclosed
WO-1993016999-A1 BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1993-09-02 WO disclosed